| Siphath Chrea, MD | |
|
3215 Columbia Pike Ste 103, Arlington, VA 22204-4359 | |
| (703) 486-0716 | |
| (703) 486-0716 |
| Full Name | Siphath Chrea |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 3215 Columbia Pike Ste 103, Arlington, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851400469 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 0101036442 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Siphath Chrea, MD 3215 Columbia Pike Ste 103, Arlington, VA 22204-4359 Ph: (703) 486-0716 | Siphath Chrea, MD 3215 Columbia Pike Ste 103, Arlington, VA 22204-4359 Ph: (703) 486-0716 |
News Archive
Researchers from the University of Southampton have identified why some people may become resistant to monoclonal antibodies, a common type of immunotherapy used in lymphoma treatment.
Cannabinoids, a class of prescription pills that contain synthetically-made chemicals found in marijuana, are associated with a 64 per cent increase in death among older adults with chronic obstructive pulmonary disease (COPD), according to the first published data on the impact of cannabinoids on the respiratory health of individuals with the lung disease.
TSYS announced today that it has signed a new long-term agreement with U.S. Bank. As part of the agreement, TSYS will continue to support the bank's commercial card payment services, as well as become its exclusive partner in providing card processing services for the bank's Consumer Directed Healthcare (CDH) benefit cards, issued by its Healthcare Payment Solutions business line.
In this study, 45 women who experienced premature labor (before 37 weeks gestation) were randomly divided into treatment and observation groups. The treatment group received twice-weekly 341-mg doses of progesterone until week 36.
Inspiration Biopharmaceuticals, Inc. today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds.
› Verified 5 days ago
Zhobin Shoja, MD General Practice Medicare: Medicare Enrolled Practice Location: 1301 S Joyce St, Arlington, VA 22202 Phone: 703-348-9111 | |
Dr. Alondra Mali Ayala Jimenez, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 2501 N Glebe Rd, Arlington, VA 22207 Phone: 703-776-3626 Fax: 888-367-1898 | |
Thuan Dinh Ngo, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 3801 N. Fairfax Drive, Suite 52, Arlington, VA 22203 Phone: 703-524-1025 Fax: 703-524-1021 | |
Dr. Robert Francis Byrne, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 2333 S Nash St, Arlington, VA 22202 Phone: 703-892-9109 Fax: 703-892-0688 | |
Ms. Marie Louise Schum-brady, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 3500 14th St N, Arlington, VA 22201 Phone: 703-527-5384 Fax: 703-527-5881 | |
Dr. David Brooks Winter, DO General Practice Medicare: Not Enrolled in Medicare Practice Location: 927 N Kenmore St, Arlington, VA 22201 Phone: 703-524-7728 Fax: 703-524-4577 | |
Dr. Kirsten Van Steenberg Ball, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 5556 16th St N, Arlington, VA 22205 Phone: 703-220-5825 |